AMPE Related Corporate News
-
Ampio Pharma (AMPE) Reports Significant Data from Optina Trial on DME
-
Ampio (AMPE) Will Proceed with Zertane Development Following Positive Pre-IND Meetings
-
Ampio Pharma (AMPE) Says CRO Completes Analysis of Optina Trial for DME; Reports Significant Interaction
-
Ampio (AMPE) Completes Pre-IND Meeting with FDA's CBER for Ampion
-
Ampio Pharma (AMPE) Reports Statistically Significant Data from Ampion in the Knee Analysis
-
Ampio (AMPE) Gets U.S. Patent for DME Drug Optina
-
Ampio (AMPE) Submits Pre-IND Package on Zertane to FDA
-
Ampio (AMPE) Reaches Agreement for Zertane CTD Preparation in Australia
-
Ampio Pharma (AMPE) Enters Exclusive Zertane License Agreement with FMBFarma
-
Ampio (AMPE) Gets Additional Patent for Ampion
-
Ampio Pharma (AMPE) Issues Prelim. Update on Optina Clinical Trial; Concluded Study Ahead of Schedule, to Request Meeting with FDA
-
Ampio (AMPE) Expands AIK Enrollment in Australia
-
Ampio Pharma (AMPE) Files Prospectus for Common Stock Offering
-
Ampio Pharma (AMPE) Believes Short-Seller Allegations are 'Factually Inaccurate'
-
Ampio Pharma (AMPE) Reports Low-Dose Intranasal Danazol has Impact on Allergic Rhinitis
-
Ampio Pharma (AMPE) Reports Positive Data from Zertane Phase III in Patients with PE
-
Ampio Pharmaceuticals (AMPE) Begins Trading on the NASDAQ Capital Market on May 19
Back to AMPE Stock Lookup
